Expertise in
29
conditions

Dr. Mark E. Molitch

Endocrinology
Northwestern Medical Faculty Foundation
680 N Lake Shore Dr Ste 1000, 
Chicago, IL 
Accepting New Patients
Referral required
Before you request
Expertise in
29
conditions
Northwestern Medical Faculty Foundation
680 N Lake Shore Dr Ste 1000, 
Chicago, IL 

Overview

Mark Molitch is an Endocrinologist practicing medicine in Chicago, Illinois.

Dr. Molitch is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Acromegaloid Facial Appearance Syndrome, Hypertrichosis-Acromegaloid Facial Appearance Syndrome, Acromegaly, Diabetic Nephropathy, and Hormone Replacement Therapy (HRT).

He is actively involved in clinical research, co-authoring 152 peer reviewed articles and participating in 6 clinical trials. Dr. Molitch is currently accepting new patients.

Specialties

Endocrinology

Licenses

Internal Medicine in IL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Northwestern Medical Faculty Foundation
680 N Lake Shore Dr Ste 1000, Chicago, IL 60611

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Diabetes Prevention Program Outcomes Study
Diabetes Prevention Program Outcomes Study
Enrollment Status: Completed
Publish Date: July 30, 2026
Intervention Type: Behavioral, Drug
Study Drug: Metformin
Study Phase: Phase 3
An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: June 19, 2025
Intervention Type: Drug
Study Drug: Levoketoconazole
Study Phase: Phase 3
An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Osilodrostat
An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Osilodrostat
Enrollment Status: Completed
Publish Date: December 18, 2024
Intervention Type: Drug
Study Drug: Osilodrostat
Study Phase: Phase 2
A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: November 08, 2022
Intervention Type: Drug
Study Phase: Phase 3
PERL (Preventing Early Renal Loss in Diabetes) Continuous Glucose Monitoring (CGM) Study
PERL (Preventing Early Renal Loss in Diabetes) Continuous Glucose Monitoring (CGM) Study
Enrollment Status: Completed
Publish Date: March 29, 2022
Intervention Type: Other, Drug
Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
Enrollment Status: Completed
Publish Date: January 06, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

152 Total Publications

Debate: Surgery as Initial Therapy for Microprolactinoma.
Debate: Surgery as Initial Therapy for Microprolactinoma.
Journal: The Journal of clinical endocrinology and metabolism
Published: June 06, 2025
Similar Doctors
Expertise in
10
conditions
Dr. Peter A. Kopp
Endocrinology
Expertise in
10
conditions
Dr. Peter A. Kopp
Endocrinology
Referral required
Before you request

Northwestern Medicine Bone Health & Osteoporosis Program

675 N Saint Clair St Ste 14-100, 
Chicago, IL 
 (0.1 miles away)
312-695-7970
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Peter Kopp is an Endocrinologist practicing medicine in Chicago, Illinois. Dr. Kopp is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Thyroid Storm, Thyroid Cancer, Papillary Thyroid Cancer, Thyroidectomy, and Hormone Replacement Therapy (HRT). Dr. Kopp is currently accepting new patients.

Expertise in
7
conditions
Dr. William L. Lowe
Endocrinology
Expertise in
7
conditions
Dr. William L. Lowe
Endocrinology
Referral required
Before you request

Northwestern Medical Facility Foundation

675 N Saint Clair St Ste 14-100, 
Chicago, IL 
 (0.1 miles away)
312-695-7970
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

William Lowe is an Endocrinologist practicing medicine in Chicago, Illinois. Dr. Lowe is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Infant Hyperglycemia, Gestational Diabetes, Obesity in Children, Obesity, and Islet Cell Transplantation. Dr. Lowe is currently accepting new patients.

Expertise in
41
conditions
Expertise in
41
conditions
Referral required
Before you request

Loyola University Medical Center

6800 N Frontage Rd, 
Burr Ridge, IL 
 (18.1 miles away)
708-327-1000
Languages Spoken:
English, Filipino
See accepted insurances
Accepting New Patients
Offers Telehealth

Pauline Camacho is an Endocrinologist practicing medicine in Burr Ridge, Illinois. Dr. Camacho is highly rated in 41 conditions, according to our data. Her clinical expertise encompasses Osteoporosis, Postmenopausal Osteoporosis, Juvenile Primary Osteoporosis, Hyperparathyroidism, and Parathyroidectomy. Dr. Camacho is currently accepting new patients.

Frequently Asked Questions about Dr. Mark E. Molitch

How do I make an appointment with Dr. Mark E. Molitch?

You can book an appointment with Dr. Mark E. Molitch by calling their office at 312-695-9797. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mark E. Molitch a top-rated expert for Acromegaloid Facial Appearance Syndrome?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mark E. Molitch is classified as an Elite expert for Acromegaloid Facial Appearance Syndrome, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mark E. Molitch specialize in?

While Dr. Mark E. Molitch is a Endocrinology, they have specific expertise in Acromegaloid Facial Appearance Syndrome, Hypertrichosis-Acromegaloid Facial Appearance Syndrome, and Acromegaly. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Endocrinology.

Does Dr. Mark E. Molitch participate in research or clinical trials?

Yes. Dr. Mark E. Molitch has published 152 articles and abstracts on conditions like Acromegaloid Facial Appearance Syndrome. You can view a list of Dr. Mark E. Molitch's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mark E. Molitch accept my insurance?

Dr. Mark E. Molitch accepts most major insurance plans, including Aetna and Cigna. We recommend calling the office directly at 312-695-9797 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Molitch's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 19 Advanced Conditions
View All 24 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile